


**【S-2】**

## **Variants in genes in the hormone-related pathway and risk of biliary tract cancer and stones: A population-based study**


Sue Kyung Park

*Seoul National University, Korea*



### Contents

- Backgrounds
- Objectives
- Materials and Methods
- Results
- Discussion
- Conclusion



### Backgrounds

- Uncommon tumors under 1%
- Encompassing cancer of the gallbladder, extrahepatic bile duct, and ampulla of Vater
- Origin: 46% Gallbladder, 27% Bile Duct, & 22% Ampulla of Vater

## Incidence

- Incidence is rising rapidly in Shanghai, China


## Previous studies

- GB ca. is that displaying a female preponderance, with incidence being 3-4 times more common among women (Pandey 2003)
- Primary risk factor of biliary tract cancer, as reported in all studies, is gallstone.
- Gallstones also occur more frequently in women than in men.


- Endogenous & exogenous estrogens and pregnancies  
→ increase the risk of BT stones including gallstones (Lambe 1993; Scragg 1984)
- Early menarche, late menopause, multiple pregnancies and childbirth, and the use of HRT In women  
→ increased the risk of BT cancers (Pandey 2003; Tavani 1996; Moerman 1994; Scragg 1984; Everson 1982).


- These results suggest that endogenous hormones can be involved in causal pathway of BT cancers and stones.

## Rationale



## Pathway of hormone biosynthesis & metabolism







### Materials and Methods

#### Shanghai Biliary Tract Cancer Study :

- Population-based case-control study conducted in Shanghai, China.
- designed to investigate the etiology of BTC
- conducted by the National Cancer Institute in collaboration with the Shanghai Cancer Institute from June, 1997 to May, 2001
- IRB of the U.S. NCI and the SCC approved the study protocol.

- Cancer case ascertainment: >95% of all cancer cases.
- Histological diagnoses of cancers: 70% of cancer cases (others - clinically confirmed)
- Nearly 100% of cancer cases and controls were assessed for gallstones



### Data collection

#### ■ Interviews

- demographic factors;
- consumption of cigarettes, alcohol, and tea;
- medical history;
- family history of cancers;
- reproductive history and exogenous hormone use (females only);
- diet;
- occupation.
- physical development and activity;

### Data collection

For checking accuracy and reliability,

- were tape recorded
  - reviewed to ensure that they were conducted uniformly among participants and that the data were recorded accurately
  - re-interview: 5% of the study subjects, who were randomly selected within 3 months after the enrollment.
- Concordance rate: 90%.

### Data collection

- To obtain information on disease characteristics  
→ medical records of cases were abstracted

### Gallstone detection

- For cancer or stone cases – questionnaires, medical record review & clinical diagnostic examinations (abdominal ultrasound, CT, MRI, and/or ERCP)
- For controls – questionnaires and abdominal ultrasonography (85%).

### Blood collection

- Genomic DNA for genotype analyses was isolated from buffy coat or whole blood samples.
- 80% of subjects that gave consent gave overnight fasting blood samples.

### Selection of Genes and SNPs

#### Gene selection

- Pathway of hormone metabolism related to gallstone and/or biliary tract cancer pathogenesis
- Assays were available at the time of analysis at the NCI Core Genotyping Facility (CGF).



#### SNP selection

- With functional information at the time of analysis and known possible functional significances
- Rare allele frequency in Asian >5%
- Validated assay techniques

### 9 Genes: 18 SNPs

#### ▪ Hormone biosynthesis and metabolism

- Cyp1A1: EX7+131A>G; IVS1+606T>G
- CYP1B1: EX2+143C>G; EX3+251G>C
- COMT: EX3-104C>T; EX4-76C>G>T
- HSB3B2: EX4-133C>T; EX4-88C>G
- HSB17B3: EX11+43G>A
- HSB17B1: Ex1-486G>A
- SRD5A2: Ex1-17G>C
- CYP19: Ex4-57A>G; IVS4-76A>G  
IVS7-106T>G; Ex8+47C>T  
IVS9-53A>G>T; Ex11+410G>T

#### ▪ Hormone transport

- SHBG: EX8+6G>A

## Genotyping

### Genotyping

- Taqman Assays



### Hardy-Weinberg equilibrium

- Population controls - no deviation from HWE ( $p > 0.05$ ).

## Reliability of Genotyping

- Laboratory personnel - blinded to all cases & controls
- Selected total 80 samples (4 repeat samples from 20 individuals)
- 97% concordance
- Success rates of each genotyping - >96%

## Statistical Analysis

### SNP Effect

- Age & Sex-adjusted, OR (95% CI): unconditional logistic regression
- Referent category – the most frequent genotype with the more frequent allele
- Comparisons


GB cancer cases - control subjects without a history of cholecystectomy  
 BD and AV cancers - all controls.  
 Stones - all controls without stones and cholecystectomy





- Multiple SNP comparisons - a summary  $p$ -value of the overall association using Simes' global test
- Stratified analyses by putative confounding factors (biliary stones, obesity, diabetes, consumption of cigarette and alcohol, and female history of reproduction and use of oral contraceptives)

## Haplotype Association for CYP19 genetic polymorphisms

- Linkage disequilibrium (LD) between loci exhibiting genetic variation among controls – pairwise Lewontin's  $D'$  and  $r^2$  values using Haploview (v 3.11)
- Risks of haplotypes – age and sex adjusted OR (95% CI) using Haplostats (R-v 2.0.1; expectation-maximization algorithm)
- To assess overall differences in haplotype frequencies – global score test

## Main effects - ORs (95% CIs)





### Haplotype analysis for Cyp19

	GB ca	BD ca	AV ca	Stone
CYP19	OR (95% CI) <sup>1</sup>	OR (95% CI) <sup>1</sup>	OR (95% CI) <sup>1</sup>	OR (95% CI) <sup>1</sup>
AAGCTT	1.0 (reference)	1.0 (reference)	1.0 (reference)	1.0 (reference)
GGCCTT	1.1 (0.7-1.6)	1.1 (0.7-1.6)	1.4 (0.7-2.9)	1.1 (0.8-1.5)
GGTCG	1.0 (0.8-1.3)	1.0 (0.8-1.3)	1.1 (0.8-1.8)	1.2 (1.0-1.4)
G	1.0 (0.7-1.3)	1.0 (0.7-1.3)	1.1 (0.6-2.0)	1.0 (0.8-1.2)
GGTTGT				
<i>p</i> -global test	0.99	0.53	0.79	0.44

### Multiple comparison (summary *p*-values)

	GB ca	BD ca	AV ca	Stone
	Summary <i>p</i>	Summary <i>p</i>	Summary <i>p</i>	Summary <i>p</i>
E-biosynthesis pathway	0.012	ns	ns	ns
E-metabolism pathway	0.032	ns	0.036	ns
A-biosynthesis pathway	ns	ns	ns	0.056

## Strengths and Limitations

### Strengths

- Largest interdisciplinary study of biliary tract cancers
- High case ascertainment
- High response rate
- Minimizing misclassification bias
- Complete gallstone assessment
- First study to investigate multiple genes and SNPs in lipid metabolism pathway

### Limitations

- Small number of ampulla of Vater cancers
- May limit formal test for interactions
- Results may not be generalizable to non-Asian ethnic groups

## Acknowledgments

### National Cancer Institute

- Ann Hsing, Ph.D.
- Jinbo Chen, Ph.D.
- Philip Rosenberg, Ph.D.
- Eric Chen, Ph.D.
- Lori Sakoda, M.P.H.
- Meredith Yeager, Ph.D.
- Robert Welch, M.S.
- Stephen Chanock, M.D.
- Joseph F. Fraumeni, Jr., M.D.

### Shanghai Cancer Institute and Hospitals

- Yu-Tang Gao, M.D.
- Jie Deng, M.D.
- Ming-Chang Sheng, M.D.
- Bin-Sheng Wang, M.D.
- Tian-Quan Han, M.D.
- Bai-He Zhang, M.D.

### MD Anderson Cancer Center Westat

- Asif Rashid, M.D.
- Hope Cohen-Webb, M.P.H.
- Shelley Niwa, M.A.